nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—ESR1—urinary bladder cancer	0.624	1	CbGaD
Danazol—AR—scrotum—urinary bladder cancer	0.018	0.179	CbGeAlD
Danazol—AR—penis—urinary bladder cancer	0.00814	0.0809	CbGeAlD
Danazol—CCL2—prostate gland—urinary bladder cancer	0.00464	0.0461	CbGeAlD
Danazol—CCL2—seminal vesicle—urinary bladder cancer	0.00393	0.039	CbGeAlD
Danazol—CCL2—epithelium—urinary bladder cancer	0.00341	0.0339	CbGeAlD
Danazol—CCL2—smooth muscle tissue—urinary bladder cancer	0.00329	0.0327	CbGeAlD
Danazol—GNRHR—female reproductive system—urinary bladder cancer	0.00325	0.0323	CbGeAlD
Danazol—CCL2—renal system—urinary bladder cancer	0.00316	0.0314	CbGeAlD
Danazol—CCL2—urethra—urinary bladder cancer	0.00311	0.0309	CbGeAlD
Danazol—CYP3A4—urine—urinary bladder cancer	0.00297	0.0295	CbGeAlD
Danazol—SHBG—prostate gland—urinary bladder cancer	0.00271	0.0269	CbGeAlD
Danazol—CCL2—female reproductive system—urinary bladder cancer	0.00253	0.0252	CbGeAlD
Danazol—PGR—prostate gland—urinary bladder cancer	0.00244	0.0242	CbGeAlD
Danazol—CCL2—vagina—urinary bladder cancer	0.00229	0.0228	CbGeAlD
Danazol—CYP19A1—prostate gland—urinary bladder cancer	0.0022	0.0218	CbGeAlD
Danazol—AR—prostate gland—urinary bladder cancer	0.00194	0.0193	CbGeAlD
Danazol—ESR1—prostate gland—urinary bladder cancer	0.00191	0.019	CbGeAlD
Danazol—PGR—epithelium—urinary bladder cancer	0.00179	0.0178	CbGeAlD
Danazol—PGR—smooth muscle tissue—urinary bladder cancer	0.00173	0.0172	CbGeAlD
Danazol—AR—seminal vesicle—urinary bladder cancer	0.00164	0.0163	CbGeAlD
Danazol—CCL2—lymph node—urinary bladder cancer	0.00148	0.0147	CbGeAlD
Danazol—SHBG—female reproductive system—urinary bladder cancer	0.00148	0.0147	CbGeAlD
Danazol—AR—epithelium—urinary bladder cancer	0.00143	0.0142	CbGeAlD
Danazol—ESR1—epithelium—urinary bladder cancer	0.0014	0.0139	CbGeAlD
Danazol—AR—smooth muscle tissue—urinary bladder cancer	0.00138	0.0137	CbGeAlD
Danazol—ESR1—smooth muscle tissue—urinary bladder cancer	0.00135	0.0134	CbGeAlD
Danazol—SHBG—vagina—urinary bladder cancer	0.00134	0.0133	CbGeAlD
Danazol—PGR—female reproductive system—urinary bladder cancer	0.00133	0.0132	CbGeAlD
Danazol—AR—renal system—urinary bladder cancer	0.00132	0.0132	CbGeAlD
Danazol—AR—urethra—urinary bladder cancer	0.0013	0.0129	CbGeAlD
Danazol—ESR1—renal system—urinary bladder cancer	0.0013	0.0129	CbGeAlD
Danazol—Trilostane—ESR2—urinary bladder cancer	0.00121	0.174	CrCbGaD
Danazol—PGR—vagina—urinary bladder cancer	0.0012	0.012	CbGeAlD
Danazol—CYP19A1—female reproductive system—urinary bladder cancer	0.0012	0.0119	CbGeAlD
Danazol—AR—female reproductive system—urinary bladder cancer	0.00106	0.0105	CbGeAlD
Danazol—ESR1—female reproductive system—urinary bladder cancer	0.00104	0.0103	CbGeAlD
Danazol—Quinestrol—ESR1—urinary bladder cancer	0.000986	0.141	CrCbGaD
Danazol—AR—vagina—urinary bladder cancer	0.00096	0.00953	CbGeAlD
Danazol—ESR1—vagina—urinary bladder cancer	0.000942	0.00936	CbGeAlD
Danazol—PGR—lymph node—urinary bladder cancer	0.000779	0.00774	CbGeAlD
Danazol—Mestranol—ESR1—urinary bladder cancer	0.000747	0.107	CrCbGaD
Danazol—Trilostane—ESR1—urinary bladder cancer	0.000747	0.107	CrCbGaD
Danazol—Desogestrel—ESR1—urinary bladder cancer	0.000738	0.106	CrCbGaD
Danazol—CYP3A4—renal system—urinary bladder cancer	0.000726	0.00721	CbGeAlD
Danazol—CYP19A1—lymph node—urinary bladder cancer	0.000701	0.00697	CbGeAlD
Danazol—AR—lymph node—urinary bladder cancer	0.000621	0.00617	CbGeAlD
Danazol—ESR1—lymph node—urinary bladder cancer	0.000609	0.00605	CbGeAlD
Danazol—Etonogestrel—ESR1—urinary bladder cancer	0.000597	0.0855	CrCbGaD
Danazol—CYP3A4—female reproductive system—urinary bladder cancer	0.000581	0.00577	CbGeAlD
Danazol—Ethinyl Estradiol—ESR2—urinary bladder cancer	0.000578	0.0827	CrCbGaD
Danazol—Levonorgestrel—ESR1—urinary bladder cancer	0.000423	0.0605	CrCbGaD
Danazol—Fluoxymesterone—ESR1—urinary bladder cancer	0.000403	0.0576	CrCbGaD
Danazol—Ethinyl Estradiol—ESR1—urinary bladder cancer	0.000356	0.051	CrCbGaD
Danazol—Flushing—Cisplatin—urinary bladder cancer	0.000338	0.00265	CcSEcCtD
Danazol—Back pain—Gemcitabine—urinary bladder cancer	0.000329	0.00258	CcSEcCtD
Danazol—Photosensitivity—Methotrexate—urinary bladder cancer	0.000329	0.00258	CcSEcCtD
Danazol—Fluid retention—Doxorubicin—urinary bladder cancer	0.000327	0.00257	CcSEcCtD
Danazol—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000323	0.00254	CcSEcCtD
Danazol—Tachycardia—Thiotepa—urinary bladder cancer	0.000322	0.00253	CcSEcCtD
Danazol—Alopecia—Cisplatin—urinary bladder cancer	0.000322	0.00253	CcSEcCtD
Danazol—Erythema multiforme—Etoposide—urinary bladder cancer	0.000316	0.00248	CcSEcCtD
Danazol—Vision blurred—Fluorouracil—urinary bladder cancer	0.000315	0.00248	CcSEcCtD
Danazol—Flushing—Etoposide—urinary bladder cancer	0.00031	0.00243	CcSEcCtD
Danazol—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00031	0.00243	CcSEcCtD
Danazol—Photosensitivity—Epirubicin—urinary bladder cancer	0.000308	0.00242	CcSEcCtD
Danazol—Visual disturbance—Methotrexate—urinary bladder cancer	0.000305	0.00239	CcSEcCtD
Danazol—Muscle spasms—Cisplatin—urinary bladder cancer	0.000305	0.00239	CcSEcCtD
Danazol—Leukopenia—Gemcitabine—urinary bladder cancer	0.000305	0.00239	CcSEcCtD
Danazol—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000301	0.00236	CcSEcCtD
Danazol—Chills—Etoposide—urinary bladder cancer	0.0003	0.00235	CcSEcCtD
Danazol—Leukopenia—Fluorouracil—urinary bladder cancer	0.0003	0.00235	CcSEcCtD
Danazol—Vision blurred—Cisplatin—urinary bladder cancer	0.000299	0.00235	CcSEcCtD
Danazol—Tremor—Cisplatin—urinary bladder cancer	0.000297	0.00233	CcSEcCtD
Danazol—Paraesthesia—Thiotepa—urinary bladder cancer	0.000297	0.00233	CcSEcCtD
Danazol—Alopecia—Etoposide—urinary bladder cancer	0.000295	0.00232	CcSEcCtD
Danazol—Hypertension—Gemcitabine—urinary bladder cancer	0.000294	0.00231	CcSEcCtD
Danazol—Dyspepsia—Thiotepa—urinary bladder cancer	0.000291	0.00228	CcSEcCtD
Danazol—Convulsion—Fluorouracil—urinary bladder cancer	0.00029	0.00228	CcSEcCtD
Danazol—Arthralgia—Gemcitabine—urinary bladder cancer	0.00029	0.00227	CcSEcCtD
Danazol—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000286	0.00225	CcSEcCtD
Danazol—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000285	0.00224	CcSEcCtD
Danazol—Fatigue—Thiotepa—urinary bladder cancer	0.000285	0.00223	CcSEcCtD
Danazol—Leukopenia—Cisplatin—urinary bladder cancer	0.000284	0.00223	CcSEcCtD
Danazol—Constipation—Thiotepa—urinary bladder cancer	0.000282	0.00222	CcSEcCtD
Danazol—Back pain—Etoposide—urinary bladder cancer	0.000281	0.00221	CcSEcCtD
Danazol—Muscle spasms—Etoposide—urinary bladder cancer	0.000279	0.00219	CcSEcCtD
Danazol—Oedema—Gemcitabine—urinary bladder cancer	0.000278	0.00218	CcSEcCtD
Danazol—Irritability—Methotrexate—urinary bladder cancer	0.000276	0.00217	CcSEcCtD
Danazol—Convulsion—Cisplatin—urinary bladder cancer	0.000275	0.00216	CcSEcCtD
Danazol—Mood swings—Methotrexate—urinary bladder cancer	0.000274	0.00215	CcSEcCtD
Danazol—Oedema—Fluorouracil—urinary bladder cancer	0.000273	0.00214	CcSEcCtD
Danazol—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000272	0.00213	CcSEcCtD
Danazol—Anxiety—Cisplatin—urinary bladder cancer	0.000269	0.00211	CcSEcCtD
Danazol—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000269	0.00211	CcSEcCtD
Danazol—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000267	0.0021	CcSEcCtD
Danazol—Tachycardia—Fluorouracil—urinary bladder cancer	0.000267	0.00209	CcSEcCtD
Danazol—Migraine—Epirubicin—urinary bladder cancer	0.000266	0.00209	CcSEcCtD
Danazol—Affect lability—Epirubicin—urinary bladder cancer	0.000266	0.00209	CcSEcCtD
Danazol—Urticaria—Thiotepa—urinary bladder cancer	0.000262	0.00206	CcSEcCtD
Danazol—Vertigo—Etoposide—urinary bladder cancer	0.000261	0.00205	CcSEcCtD
Danazol—Body temperature increased—Thiotepa—urinary bladder cancer	0.000261	0.00205	CcSEcCtD
Danazol—Leukopenia—Etoposide—urinary bladder cancer	0.00026	0.00204	CcSEcCtD
Danazol—Oedema—Cisplatin—urinary bladder cancer	0.000259	0.00203	CcSEcCtD
Danazol—Mood swings—Epirubicin—urinary bladder cancer	0.000256	0.00201	CcSEcCtD
Danazol—Loss of consciousness—Etoposide—urinary bladder cancer	0.000255	0.002	CcSEcCtD
Danazol—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000254	0.00199	CcSEcCtD
Danazol—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000253	0.00199	CcSEcCtD
Danazol—Tachycardia—Cisplatin—urinary bladder cancer	0.000253	0.00198	CcSEcCtD
Danazol—Convulsion—Etoposide—urinary bladder cancer	0.000252	0.00198	CcSEcCtD
Danazol—Hypertension—Etoposide—urinary bladder cancer	0.000251	0.00197	CcSEcCtD
Danazol—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00025	0.00196	CcSEcCtD
Danazol—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000249	0.00196	CcSEcCtD
Danazol—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000249	0.00195	CcSEcCtD
Danazol—Eosinophilia—Methotrexate—urinary bladder cancer	0.000247	0.00194	CcSEcCtD
Danazol—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000247	0.00194	CcSEcCtD
Danazol—Migraine—Doxorubicin—urinary bladder cancer	0.000246	0.00193	CcSEcCtD
Danazol—Affect lability—Doxorubicin—urinary bladder cancer	0.000246	0.00193	CcSEcCtD
Danazol—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000245	0.00192	CcSEcCtD
Danazol—Pancreatitis—Methotrexate—urinary bladder cancer	0.000245	0.00192	CcSEcCtD
Danazol—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00024	0.00189	CcSEcCtD
Danazol—Fatigue—Gemcitabine—urinary bladder cancer	0.00024	0.00188	CcSEcCtD
Danazol—Constipation—Gemcitabine—urinary bladder cancer	0.000238	0.00186	CcSEcCtD
Danazol—Mood swings—Doxorubicin—urinary bladder cancer	0.000237	0.00186	CcSEcCtD
Danazol—Asthenia—Thiotepa—urinary bladder cancer	0.000237	0.00186	CcSEcCtD
Danazol—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000236	0.00185	CcSEcCtD
Danazol—Pruritus—Thiotepa—urinary bladder cancer	0.000234	0.00183	CcSEcCtD
Danazol—Paraesthesia—Cisplatin—urinary bladder cancer	0.000233	0.00182	CcSEcCtD
Danazol—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000232	0.00182	CcSEcCtD
Danazol—Tachycardia—Etoposide—urinary bladder cancer	0.000232	0.00182	CcSEcCtD
Danazol—Eosinophilia—Epirubicin—urinary bladder cancer	0.000232	0.00182	CcSEcCtD
Danazol—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000229	0.0018	CcSEcCtD
Danazol—Pancreatitis—Epirubicin—urinary bladder cancer	0.000229	0.0018	CcSEcCtD
Danazol—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000229	0.00179	CcSEcCtD
Danazol—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000228	0.00179	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000221	0.00173	CcSEcCtD
Danazol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00022	0.00172	CcSEcCtD
Danazol—Dizziness—Thiotepa—urinary bladder cancer	0.000218	0.00171	CcSEcCtD
Danazol—Urticaria—Fluorouracil—urinary bladder cancer	0.000217	0.0017	CcSEcCtD
Danazol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000216	0.00169	CcSEcCtD
Danazol—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000214	0.00168	CcSEcCtD
Danazol—Sweating—Methotrexate—urinary bladder cancer	0.000214	0.00168	CcSEcCtD
Danazol—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000213	0.00167	CcSEcCtD
Danazol—Paraesthesia—Etoposide—urinary bladder cancer	0.000213	0.00167	CcSEcCtD
Danazol—Weight increased—Epirubicin—urinary bladder cancer	0.000213	0.00167	CcSEcCtD
Danazol—Haematuria—Methotrexate—urinary bladder cancer	0.000212	0.00167	CcSEcCtD
Danazol—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000212	0.00166	CcSEcCtD
Danazol—Vomiting—Thiotepa—urinary bladder cancer	0.00021	0.00165	CcSEcCtD
Danazol—Rash—Thiotepa—urinary bladder cancer	0.000208	0.00163	CcSEcCtD
Danazol—Dermatitis—Thiotepa—urinary bladder cancer	0.000208	0.00163	CcSEcCtD
Danazol—Headache—Thiotepa—urinary bladder cancer	0.000207	0.00162	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000207	0.00162	CcSEcCtD
Danazol—Body temperature increased—Cisplatin—urinary bladder cancer	0.000205	0.00161	CcSEcCtD
Danazol—Fatigue—Etoposide—urinary bladder cancer	0.000205	0.0016	CcSEcCtD
Danazol—Jaundice—Epirubicin—urinary bladder cancer	0.000203	0.00159	CcSEcCtD
Danazol—Constipation—Etoposide—urinary bladder cancer	0.000203	0.00159	CcSEcCtD
Danazol—Haemoglobin—Methotrexate—urinary bladder cancer	0.000201	0.00158	CcSEcCtD
Danazol—Haemorrhage—Methotrexate—urinary bladder cancer	0.0002	0.00157	CcSEcCtD
Danazol—Sweating—Epirubicin—urinary bladder cancer	0.0002	0.00157	CcSEcCtD
Danazol—Progesterone—ESR1—urinary bladder cancer	0.0002	0.0286	CrCbGaD
Danazol—Asthenia—Gemcitabine—urinary bladder cancer	0.000199	0.00156	CcSEcCtD
Danazol—Haematuria—Epirubicin—urinary bladder cancer	0.000199	0.00156	CcSEcCtD
Danazol—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000198	0.00155	CcSEcCtD
Danazol—Weight increased—Doxorubicin—urinary bladder cancer	0.000197	0.00155	CcSEcCtD
Danazol—Pruritus—Gemcitabine—urinary bladder cancer	0.000197	0.00154	CcSEcCtD
Danazol—Nausea—Thiotepa—urinary bladder cancer	0.000196	0.00154	CcSEcCtD
Danazol—Pruritus—Fluorouracil—urinary bladder cancer	0.000193	0.00152	CcSEcCtD
Danazol—Visual impairment—Methotrexate—urinary bladder cancer	0.000193	0.00151	CcSEcCtD
Danazol—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000191	0.0015	CcSEcCtD
Danazol—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000189	0.00148	CcSEcCtD
Danazol—Urticaria—Etoposide—urinary bladder cancer	0.000188	0.00148	CcSEcCtD
Danazol—Haemoglobin—Epirubicin—urinary bladder cancer	0.000188	0.00148	CcSEcCtD
Danazol—Jaundice—Doxorubicin—urinary bladder cancer	0.000188	0.00148	CcSEcCtD
Danazol—Body temperature increased—Etoposide—urinary bladder cancer	0.000188	0.00147	CcSEcCtD
Danazol—Haemorrhage—Epirubicin—urinary bladder cancer	0.000187	0.00147	CcSEcCtD
Danazol—Asthenia—Cisplatin—urinary bladder cancer	0.000186	0.00146	CcSEcCtD
Danazol—Sweating—Doxorubicin—urinary bladder cancer	0.000185	0.00145	CcSEcCtD
Danazol—Haematuria—Doxorubicin—urinary bladder cancer	0.000184	0.00144	CcSEcCtD
Danazol—Dizziness—Fluorouracil—urinary bladder cancer	0.000181	0.00142	CcSEcCtD
Danazol—Visual impairment—Epirubicin—urinary bladder cancer	0.00018	0.00142	CcSEcCtD
Danazol—Chills—Methotrexate—urinary bladder cancer	0.000179	0.00141	CcSEcCtD
Danazol—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000177	0.00139	CcSEcCtD
Danazol—Alopecia—Methotrexate—urinary bladder cancer	0.000177	0.00139	CcSEcCtD
Danazol—Vomiting—Gemcitabine—urinary bladder cancer	0.000177	0.00139	CcSEcCtD
Danazol—Rash—Gemcitabine—urinary bladder cancer	0.000175	0.00137	CcSEcCtD
Danazol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000175	0.00137	CcSEcCtD
Danazol—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000174	0.00137	CcSEcCtD
Danazol—Headache—Gemcitabine—urinary bladder cancer	0.000174	0.00137	CcSEcCtD
Danazol—Flushing—Epirubicin—urinary bladder cancer	0.000174	0.00136	CcSEcCtD
Danazol—Vomiting—Fluorouracil—urinary bladder cancer	0.000174	0.00136	CcSEcCtD
Danazol—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000173	0.00136	CcSEcCtD
Danazol—Rash—Fluorouracil—urinary bladder cancer	0.000172	0.00135	CcSEcCtD
Danazol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000172	0.00135	CcSEcCtD
Danazol—Headache—Fluorouracil—urinary bladder cancer	0.000171	0.00134	CcSEcCtD
Danazol—Asthenia—Etoposide—urinary bladder cancer	0.00017	0.00134	CcSEcCtD
Danazol—Back pain—Methotrexate—urinary bladder cancer	0.000168	0.00132	CcSEcCtD
Danazol—Chills—Epirubicin—urinary bladder cancer	0.000168	0.00132	CcSEcCtD
Danazol—Pruritus—Etoposide—urinary bladder cancer	0.000168	0.00132	CcSEcCtD
Danazol—Visual impairment—Doxorubicin—urinary bladder cancer	0.000167	0.00131	CcSEcCtD
Danazol—Alopecia—Epirubicin—urinary bladder cancer	0.000165	0.0013	CcSEcCtD
Danazol—Nausea—Gemcitabine—urinary bladder cancer	0.000165	0.00129	CcSEcCtD
Danazol—Vomiting—Cisplatin—urinary bladder cancer	0.000165	0.00129	CcSEcCtD
Danazol—Vision blurred—Methotrexate—urinary bladder cancer	0.000164	0.00129	CcSEcCtD
Danazol—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000164	0.00128	CcSEcCtD
Danazol—Rash—Cisplatin—urinary bladder cancer	0.000163	0.00128	CcSEcCtD
Danazol—Dermatitis—Cisplatin—urinary bladder cancer	0.000163	0.00128	CcSEcCtD
Danazol—Nausea—Fluorouracil—urinary bladder cancer	0.000162	0.00127	CcSEcCtD
Danazol—Flushing—Doxorubicin—urinary bladder cancer	0.000161	0.00126	CcSEcCtD
Danazol—Tension—Epirubicin—urinary bladder cancer	0.00016	0.00125	CcSEcCtD
Danazol—Nervousness—Epirubicin—urinary bladder cancer	0.000158	0.00124	CcSEcCtD
Danazol—Back pain—Epirubicin—urinary bladder cancer	0.000158	0.00124	CcSEcCtD
Danazol—Dizziness—Etoposide—urinary bladder cancer	0.000157	0.00123	CcSEcCtD
Danazol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000157	0.00123	CcSEcCtD
Danazol—Vertigo—Methotrexate—urinary bladder cancer	0.000156	0.00123	CcSEcCtD
Danazol—Leukopenia—Methotrexate—urinary bladder cancer	0.000156	0.00122	CcSEcCtD
Danazol—Chills—Doxorubicin—urinary bladder cancer	0.000155	0.00122	CcSEcCtD
Danazol—Nausea—Cisplatin—urinary bladder cancer	0.000154	0.00121	CcSEcCtD
Danazol—Vision blurred—Epirubicin—urinary bladder cancer	0.000154	0.0012	CcSEcCtD
Danazol—Alopecia—Doxorubicin—urinary bladder cancer	0.000153	0.0012	CcSEcCtD
Danazol—Convulsion—Methotrexate—urinary bladder cancer	0.000151	0.00118	CcSEcCtD
Danazol—Vomiting—Etoposide—urinary bladder cancer	0.000151	0.00118	CcSEcCtD
Danazol—Rash—Etoposide—urinary bladder cancer	0.00015	0.00117	CcSEcCtD
Danazol—Dermatitis—Etoposide—urinary bladder cancer	0.000149	0.00117	CcSEcCtD
Danazol—Headache—Etoposide—urinary bladder cancer	0.000149	0.00117	CcSEcCtD
Danazol—Arthralgia—Methotrexate—urinary bladder cancer	0.000148	0.00116	CcSEcCtD
Danazol—Tension—Doxorubicin—urinary bladder cancer	0.000148	0.00116	CcSEcCtD
Danazol—Nervousness—Doxorubicin—urinary bladder cancer	0.000146	0.00115	CcSEcCtD
Danazol—Vertigo—Epirubicin—urinary bladder cancer	0.000146	0.00115	CcSEcCtD
Danazol—Syncope—Epirubicin—urinary bladder cancer	0.000146	0.00115	CcSEcCtD
Danazol—Leukopenia—Epirubicin—urinary bladder cancer	0.000146	0.00114	CcSEcCtD
Danazol—Back pain—Doxorubicin—urinary bladder cancer	0.000146	0.00114	CcSEcCtD
Danazol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000145	0.00114	CcSEcCtD
Danazol—Palpitations—Epirubicin—urinary bladder cancer	0.000144	0.00113	CcSEcCtD
Danazol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000143	0.00112	CcSEcCtD
Danazol—Vision blurred—Doxorubicin—urinary bladder cancer	0.000142	0.00111	CcSEcCtD
Danazol—Convulsion—Epirubicin—urinary bladder cancer	0.000141	0.00111	CcSEcCtD
Danazol—Nausea—Etoposide—urinary bladder cancer	0.000141	0.00111	CcSEcCtD
Danazol—Hypertension—Epirubicin—urinary bladder cancer	0.000141	0.0011	CcSEcCtD
Danazol—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000139	0.00109	CcSEcCtD
Danazol—Arthralgia—Epirubicin—urinary bladder cancer	0.000139	0.00109	CcSEcCtD
Danazol—Anxiety—Epirubicin—urinary bladder cancer	0.000138	0.00108	CcSEcCtD
Danazol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000137	0.00108	CcSEcCtD
Danazol—Vertigo—Doxorubicin—urinary bladder cancer	0.000135	0.00106	CcSEcCtD
Danazol—Syncope—Doxorubicin—urinary bladder cancer	0.000135	0.00106	CcSEcCtD
Danazol—Leukopenia—Doxorubicin—urinary bladder cancer	0.000135	0.00106	CcSEcCtD
Danazol—Palpitations—Doxorubicin—urinary bladder cancer	0.000133	0.00105	CcSEcCtD
Danazol—Oedema—Epirubicin—urinary bladder cancer	0.000133	0.00104	CcSEcCtD
Danazol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000133	0.00104	CcSEcCtD
Danazol—Shock—Epirubicin—urinary bladder cancer	0.000131	0.00103	CcSEcCtD
Danazol—Convulsion—Doxorubicin—urinary bladder cancer	0.000131	0.00102	CcSEcCtD
Danazol—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00013	0.00102	CcSEcCtD
Danazol—Hypertension—Doxorubicin—urinary bladder cancer	0.00013	0.00102	CcSEcCtD
Danazol—Tachycardia—Epirubicin—urinary bladder cancer	0.00013	0.00102	CcSEcCtD
Danazol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000129	0.00102	CcSEcCtD
Danazol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000129	0.00101	CcSEcCtD
Danazol—Arthralgia—Doxorubicin—urinary bladder cancer	0.000128	0.00101	CcSEcCtD
Danazol—Anxiety—Doxorubicin—urinary bladder cancer	0.000128	0.001	CcSEcCtD
Danazol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000128	0.001	CcSEcCtD
Danazol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000125	0.000981	CcSEcCtD
Danazol—Oedema—Doxorubicin—urinary bladder cancer	0.000123	0.000965	CcSEcCtD
Danazol—Fatigue—Methotrexate—urinary bladder cancer	0.000123	0.000961	CcSEcCtD
Danazol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000121	0.000951	CcSEcCtD
Danazol—Shock—Doxorubicin—urinary bladder cancer	0.000121	0.00095	CcSEcCtD
Danazol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.00012	0.000945	CcSEcCtD
Danazol—Tachycardia—Doxorubicin—urinary bladder cancer	0.00012	0.000942	CcSEcCtD
Danazol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000119	0.000937	CcSEcCtD
Danazol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000119	0.000933	CcSEcCtD
Danazol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000117	0.000919	CcSEcCtD
Danazol—Fatigue—Epirubicin—urinary bladder cancer	0.000115	0.0009	CcSEcCtD
Danazol—Constipation—Epirubicin—urinary bladder cancer	0.000114	0.000892	CcSEcCtD
Danazol—Urticaria—Methotrexate—urinary bladder cancer	0.000113	0.000886	CcSEcCtD
Danazol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000112	0.000881	CcSEcCtD
Danazol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000112	0.00088	CcSEcCtD
Danazol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00011	0.000867	CcSEcCtD
Danazol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000108	0.00085	CcSEcCtD
Danazol—Fatigue—Doxorubicin—urinary bladder cancer	0.000106	0.000832	CcSEcCtD
Danazol—Urticaria—Epirubicin—urinary bladder cancer	0.000106	0.000829	CcSEcCtD
Danazol—Constipation—Doxorubicin—urinary bladder cancer	0.000105	0.000826	CcSEcCtD
Danazol—Body temperature increased—Epirubicin—urinary bladder cancer	0.000105	0.000825	CcSEcCtD
Danazol—Asthenia—Methotrexate—urinary bladder cancer	0.000102	0.0008	CcSEcCtD
Danazol—Pruritus—Methotrexate—urinary bladder cancer	0.000101	0.000789	CcSEcCtD
Danazol—Urticaria—Doxorubicin—urinary bladder cancer	9.78e-05	0.000767	CcSEcCtD
Danazol—Body temperature increased—Doxorubicin—urinary bladder cancer	9.73e-05	0.000763	CcSEcCtD
Danazol—Asthenia—Epirubicin—urinary bladder cancer	9.54e-05	0.000749	CcSEcCtD
Danazol—Pruritus—Epirubicin—urinary bladder cancer	9.41e-05	0.000738	CcSEcCtD
Danazol—Dizziness—Methotrexate—urinary bladder cancer	9.4e-05	0.000737	CcSEcCtD
Danazol—Vomiting—Methotrexate—urinary bladder cancer	9.04e-05	0.000709	CcSEcCtD
Danazol—Rash—Methotrexate—urinary bladder cancer	8.96e-05	0.000703	CcSEcCtD
Danazol—Dermatitis—Methotrexate—urinary bladder cancer	8.95e-05	0.000702	CcSEcCtD
Danazol—Headache—Methotrexate—urinary bladder cancer	8.9e-05	0.000699	CcSEcCtD
Danazol—Asthenia—Doxorubicin—urinary bladder cancer	8.83e-05	0.000693	CcSEcCtD
Danazol—Dizziness—Epirubicin—urinary bladder cancer	8.79e-05	0.00069	CcSEcCtD
Danazol—Pruritus—Doxorubicin—urinary bladder cancer	8.71e-05	0.000683	CcSEcCtD
Danazol—Vomiting—Epirubicin—urinary bladder cancer	8.46e-05	0.000663	CcSEcCtD
Danazol—Nausea—Methotrexate—urinary bladder cancer	8.44e-05	0.000662	CcSEcCtD
Danazol—Rash—Epirubicin—urinary bladder cancer	8.38e-05	0.000658	CcSEcCtD
Danazol—Dermatitis—Epirubicin—urinary bladder cancer	8.38e-05	0.000657	CcSEcCtD
Danazol—Headache—Epirubicin—urinary bladder cancer	8.33e-05	0.000654	CcSEcCtD
Danazol—Dizziness—Doxorubicin—urinary bladder cancer	8.14e-05	0.000638	CcSEcCtD
Danazol—Nausea—Epirubicin—urinary bladder cancer	7.9e-05	0.00062	CcSEcCtD
Danazol—Vomiting—Doxorubicin—urinary bladder cancer	7.82e-05	0.000614	CcSEcCtD
Danazol—Rash—Doxorubicin—urinary bladder cancer	7.76e-05	0.000609	CcSEcCtD
Danazol—Dermatitis—Doxorubicin—urinary bladder cancer	7.75e-05	0.000608	CcSEcCtD
Danazol—Headache—Doxorubicin—urinary bladder cancer	7.71e-05	0.000605	CcSEcCtD
Danazol—Nausea—Doxorubicin—urinary bladder cancer	7.31e-05	0.000573	CcSEcCtD
Danazol—CYP19A1—Metabolism—CYP4B1—urinary bladder cancer	6.96e-05	0.000494	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	6.96e-05	0.000494	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—JAG1—urinary bladder cancer	6.94e-05	0.000493	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	6.89e-05	0.00049	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	6.77e-05	0.000481	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	6.7e-05	0.000476	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—PPARG—urinary bladder cancer	6.68e-05	0.000474	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TSC1—urinary bladder cancer	6.67e-05	0.000474	CbGpPWpGaD
Danazol—PGR—Gene Expression—SMC1A—urinary bladder cancer	6.67e-05	0.000474	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—SLC19A1—urinary bladder cancer	6.57e-05	0.000467	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	6.53e-05	0.000464	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—GLI1—urinary bladder cancer	6.53e-05	0.000464	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	6.51e-05	0.000463	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—CDKN1A—urinary bladder cancer	6.51e-05	0.000463	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	6.51e-05	0.000463	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—PTEN—urinary bladder cancer	6.5e-05	0.000462	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—CXCL8—urinary bladder cancer	6.41e-05	0.000456	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	6.41e-05	0.000456	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PRSS3—urinary bladder cancer	6.4e-05	0.000455	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	6.39e-05	0.000454	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—JAG1—urinary bladder cancer	6.35e-05	0.000451	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.35e-05	0.000451	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	6.32e-05	0.000449	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	6.23e-05	0.000443	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	6.21e-05	0.000441	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	6.13e-05	0.000435	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	6.06e-05	0.000431	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	5.93e-05	0.000421	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	5.84e-05	0.000415	CbGpPWpGaD
Danazol—PGR—Gene Expression—ESR2—urinary bladder cancer	5.81e-05	0.000413	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	5.79e-05	0.000411	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	5.71e-05	0.000406	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—S100B—urinary bladder cancer	5.62e-05	0.0004	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.61e-05	0.000398	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	5.6e-05	0.000398	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—ESR1—urinary bladder cancer	5.58e-05	0.000396	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	5.47e-05	0.000388	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.44e-05	0.000386	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	5.43e-05	0.000386	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.42e-05	0.000385	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.41e-05	0.000384	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.39e-05	0.000383	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—RHOA—urinary bladder cancer	5.37e-05	0.000381	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—RHOA—urinary bladder cancer	5.33e-05	0.000379	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	5.31e-05	0.000377	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—EGFR—urinary bladder cancer	5.28e-05	0.000375	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.16e-05	0.000367	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—S100B—urinary bladder cancer	5.14e-05	0.000365	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.13e-05	0.000365	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—TYMP—urinary bladder cancer	5.12e-05	0.000364	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—PPARG—urinary bladder cancer	5.09e-05	0.000361	CbGpPWpGaD
Danazol—AR—Gene Expression—SMC1A—urinary bladder cancer	5.08e-05	0.000361	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—NCOR1—urinary bladder cancer	5.06e-05	0.000359	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.02e-05	0.000357	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	5.01e-05	0.000356	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—KRAS—urinary bladder cancer	4.99e-05	0.000354	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	4.98e-05	0.000354	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.92e-05	0.000349	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	4.89e-05	0.000347	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—RHOA—urinary bladder cancer	4.88e-05	0.000346	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.79e-05	0.000341	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.71e-05	0.000335	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—CXCL8—urinary bladder cancer	4.68e-05	0.000333	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—NAT2—urinary bladder cancer	4.63e-05	0.000329	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—NCOR1—urinary bladder cancer	4.62e-05	0.000329	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HDAC4—urinary bladder cancer	4.57e-05	0.000325	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—IL2—urinary bladder cancer	4.5e-05	0.00032	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.5e-05	0.00032	CbGpPWpGaD
Danazol—PGR—Gene Expression—NCOR1—urinary bladder cancer	4.49e-05	0.000319	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RBX1—urinary bladder cancer	4.47e-05	0.000318	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—IL2—urinary bladder cancer	4.47e-05	0.000318	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	4.46e-05	0.000317	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TERT—urinary bladder cancer	4.46e-05	0.000317	CbGpPWpGaD
Danazol—AR—Gene Expression—ESR2—urinary bladder cancer	4.43e-05	0.000314	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.4e-05	0.000313	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—CXCL8—urinary bladder cancer	4.28e-05	0.000304	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.25e-05	0.000302	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—HRAS—urinary bladder cancer	4.24e-05	0.000301	CbGpPWpGaD
Danazol—PGR—Gene Expression—ERCC2—urinary bladder cancer	4.22e-05	0.0003	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TSC1—urinary bladder cancer	4.21e-05	0.000299	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.19e-05	0.000298	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.19e-05	0.000298	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.16e-05	0.000295	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—IL2—urinary bladder cancer	4.09e-05	0.000291	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—FGFR3—urinary bladder cancer	4.09e-05	0.000291	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TERT—urinary bladder cancer	4.08e-05	0.00029	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—JAG1—urinary bladder cancer	4.01e-05	0.000285	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—RRM2—urinary bladder cancer	4e-05	0.000284	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ESR1—urinary bladder cancer	3.97e-05	0.000282	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—PPARG—urinary bladder cancer	3.92e-05	0.000278	CbGpPWpGaD
Danazol—ESR1—Gene Expression—SMC1A—urinary bladder cancer	3.91e-05	0.000278	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.9e-05	0.000277	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.85e-05	0.000273	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—GLI1—urinary bladder cancer	3.83e-05	0.000272	CbGpPWpGaD
Danazol—PGR—Generic Transcription Pathway—MYC—urinary bladder cancer	3.81e-05	0.00027	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	3.76e-05	0.000267	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—FGFR3—urinary bladder cancer	3.74e-05	0.000266	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ENO2—urinary bladder cancer	3.7e-05	0.000263	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	3.7e-05	0.000263	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.69e-05	0.000262	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.68e-05	0.000261	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ESR1—urinary bladder cancer	3.63e-05	0.000258	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	3.59e-05	0.000255	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.53e-05	0.000251	CbGpPWpGaD
Danazol—PGR—Gene Expression—ESR1—urinary bladder cancer	3.52e-05	0.00025	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CREBBP—urinary bladder cancer	3.48e-05	0.000247	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IGF1—urinary bladder cancer	3.44e-05	0.000244	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—EGFR—urinary bladder cancer	3.42e-05	0.000243	CbGpPWpGaD
Danazol—AR—Gene Expression—NCOR1—urinary bladder cancer	3.42e-05	0.000243	CbGpPWpGaD
Danazol—ESR1—Gene Expression—ESR2—urinary bladder cancer	3.41e-05	0.000242	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—S100B—urinary bladder cancer	3.24e-05	0.00023	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—KRAS—urinary bladder cancer	3.23e-05	0.00023	CbGpPWpGaD
Danazol—PGR—Gene Expression—PPARG—urinary bladder cancer	3.21e-05	0.000228	CbGpPWpGaD
Danazol—AR—Gene Expression—ERCC2—urinary bladder cancer	3.21e-05	0.000228	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CREBBP—urinary bladder cancer	3.18e-05	0.000226	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RHOA—urinary bladder cancer	3.15e-05	0.000224	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IGF1—urinary bladder cancer	3.14e-05	0.000223	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—EGFR—urinary bladder cancer	3.13e-05	0.000222	CbGpPWpGaD
Danazol—PGR—Gene Expression—CREBBP—urinary bladder cancer	3.09e-05	0.000219	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—NQO1—urinary bladder cancer	2.98e-05	0.000212	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—KRAS—urinary bladder cancer	2.96e-05	0.00021	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—NCOR1—urinary bladder cancer	2.92e-05	0.000207	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ERBB2—urinary bladder cancer	2.92e-05	0.000207	CbGpPWpGaD
Danazol—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	2.9e-05	0.000206	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.89e-05	0.000206	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—RHOA—urinary bladder cancer	2.88e-05	0.000205	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CXCL8—urinary bladder cancer	2.76e-05	0.000196	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—HRAS—urinary bladder cancer	2.75e-05	0.000195	CbGpPWpGaD
Danazol—AR—Gene Expression—ESR1—urinary bladder cancer	2.68e-05	0.000191	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—ERBB2—urinary bladder cancer	2.67e-05	0.000189	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL2—urinary bladder cancer	2.64e-05	0.000188	CbGpPWpGaD
Danazol—ESR1—Gene Expression—NCOR1—urinary bladder cancer	2.63e-05	0.000187	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RBX1—urinary bladder cancer	2.63e-05	0.000187	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.6e-05	0.000185	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CCND1—urinary bladder cancer	2.58e-05	0.000183	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TERT—urinary bladder cancer	2.57e-05	0.000183	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CXCL8—urinary bladder cancer	2.53e-05	0.00018	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.52e-05	0.000179	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—HRAS—urinary bladder cancer	2.51e-05	0.000178	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MMP9—urinary bladder cancer	2.5e-05	0.000178	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.49e-05	0.000177	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	2.49e-05	0.000177	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—PTEN—urinary bladder cancer	2.49e-05	0.000177	CbGpPWpGaD
Danazol—ESR1—Gene Expression—ERCC2—urinary bladder cancer	2.48e-05	0.000176	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TSC1—urinary bladder cancer	2.47e-05	0.000175	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.47e-05	0.000175	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.47e-05	0.000175	CbGpPWpGaD
Danazol—AR—Gene Expression—PPARG—urinary bladder cancer	2.45e-05	0.000174	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL2—urinary bladder cancer	2.42e-05	0.000172	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.41e-05	0.000171	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—EP300—urinary bladder cancer	2.37e-05	0.000168	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—FGFR3—urinary bladder cancer	2.36e-05	0.000168	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CCND1—urinary bladder cancer	2.36e-05	0.000167	CbGpPWpGaD
Danazol—AR—Gene Expression—CREBBP—urinary bladder cancer	2.35e-05	0.000167	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—JAG1—urinary bladder cancer	2.35e-05	0.000167	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—TYMS—urinary bladder cancer	2.31e-05	0.000164	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SRC—urinary bladder cancer	2.31e-05	0.000164	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ESR1—urinary bladder cancer	2.29e-05	0.000163	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MMP9—urinary bladder cancer	2.29e-05	0.000162	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	2.29e-05	0.000162	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	2.29e-05	0.000162	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—CDKN1A—urinary bladder cancer	2.28e-05	0.000162	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—PTEN—urinary bladder cancer	2.27e-05	0.000162	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.26e-05	0.00016	CbGpPWpGaD
Danazol—ESR1—Generic Transcription Pathway—MYC—urinary bladder cancer	2.23e-05	0.000159	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GPX1—urinary bladder cancer	2.19e-05	0.000156	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—EP300—urinary bladder cancer	2.17e-05	0.000154	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	2.15e-05	0.000153	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SRC—urinary bladder cancer	2.11e-05	0.00015	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MYC—urinary bladder cancer	2.07e-05	0.000147	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.03e-05	0.000144	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	2.02e-05	0.000144	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—EGFR—urinary bladder cancer	2.02e-05	0.000144	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CREBBP—urinary bladder cancer	2.01e-05	0.000143	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IGF1—urinary bladder cancer	1.98e-05	0.000141	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.92e-05	0.000136	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—KRAS—urinary bladder cancer	1.91e-05	0.000136	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—S100B—urinary bladder cancer	1.9e-05	0.000135	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MYC—urinary bladder cancer	1.89e-05	0.000134	CbGpPWpGaD
Danazol—ESR1—Gene Expression—PPARG—urinary bladder cancer	1.89e-05	0.000134	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.87e-05	0.000133	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—EGFR—urinary bladder cancer	1.85e-05	0.000131	CbGpPWpGaD
Danazol—PGR—Gene Expression—MYC—urinary bladder cancer	1.83e-05	0.00013	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—RHOA—urinary bladder cancer	1.82e-05	0.000129	CbGpPWpGaD
Danazol—ESR1—Gene Expression—CREBBP—urinary bladder cancer	1.81e-05	0.000129	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KRAS—urinary bladder cancer	1.75e-05	0.000124	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.71e-05	0.000122	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TP53—urinary bladder cancer	1.7e-05	0.000121	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	1.68e-05	0.000119	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PPARG—urinary bladder cancer	1.64e-05	0.000116	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—HRAS—urinary bladder cancer	1.62e-05	0.000115	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	1.59e-05	0.000113	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	1.57e-05	0.000112	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TP53—urinary bladder cancer	1.55e-05	0.00011	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL2—urinary bladder cancer	1.52e-05	0.000108	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TERT—urinary bladder cancer	1.51e-05	0.000107	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.49e-05	0.000106	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CCND1—urinary bladder cancer	1.49e-05	0.000106	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—HRAS—urinary bladder cancer	1.48e-05	0.000105	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MMP9—urinary bladder cancer	1.44e-05	0.000102	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.44e-05	0.000102	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—PTEN—urinary bladder cancer	1.43e-05	0.000102	CbGpPWpGaD
Danazol—AR—Gene Expression—MYC—urinary bladder cancer	1.4e-05	9.92e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	1.38e-05	9.84e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—EP300—urinary bladder cancer	1.37e-05	9.72e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.35e-05	9.6e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SRC—urinary bladder cancer	1.33e-05	9.45e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	1.29e-05	9.16e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MYC—urinary bladder cancer	1.19e-05	8.47e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	1.18e-05	8.37e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.17e-05	8.29e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—EGFR—urinary bladder cancer	1.17e-05	8.28e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	1.16e-05	8.27e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTEN—urinary bladder cancer	1.12e-05	7.99e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KRAS—urinary bladder cancer	1.1e-05	7.82e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.08e-05	7.67e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.08e-05	7.67e-05	CbGpPWpGaD
Danazol—ESR1—Gene Expression—MYC—urinary bladder cancer	1.08e-05	7.64e-05	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—EP300—urinary bladder cancer	1.07e-05	7.62e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	1.07e-05	7.57e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.05e-05	7.44e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	9.87e-06	7.01e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TP53—urinary bladder cancer	9.79e-06	6.95e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	9.36e-06	6.65e-05	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—HRAS—urinary bladder cancer	9.36e-06	6.65e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL2—urinary bladder cancer	8.94e-06	6.35e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	8.72e-06	6.19e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.71e-06	6.19e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	8.46e-06	6.01e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.43e-06	5.99e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	8.42e-06	5.98e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—EP300—urinary bladder cancer	8.03e-06	5.7e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SRC—urinary bladder cancer	7.8e-06	5.54e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.26e-06	5.16e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MYC—urinary bladder cancer	6.99e-06	4.97e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	6.84e-06	4.86e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.75e-06	4.8e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.67e-06	4.74e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.67e-06	4.74e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	6.46e-06	4.59e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.39e-06	4.54e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.27e-06	4.46e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.9e-06	4.19e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TP53—urinary bladder cancer	5.74e-06	4.08e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	5.49e-06	3.9e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.78e-06	3.4e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.59e-06	3.26e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.76e-06	2.67e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.28e-06	2.33e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.13e-06	2.22e-05	CbGpPWpGaD
